May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Short Term Visual and Anatomic Outcomes Following Intravitreal Bevacizumab in the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion
Author Affiliations & Notes
  • L. Wu
    Vitreoretinal, Instituto de Cirugia Ocular, Plaza Mayor San Jose, Costa Rica
  • T. Evans
    Vitreoretinal, Instituto de Cirugia Ocular, Plaza Mayor San Jose, Costa Rica
  • J. F. Arevalo
    Vitreoretinal, Clinica Oftalmologica Centro Caracas, Caracas, Venezuela
  • M. H. Berrocal
    Vitreoretinal, University of Puerto Rico, Santurce, Puerto Rico
  • J. A. Roca
    Vitreoretinal, Clinica Ricardo Palma, Lima, Peru
  • M. Maia
    Vitreoretinal, UNIFESP Federal University of Sao Paulo, Sao Paulo, Brazil
  • R. Costa
    Retinal Diagnostic and Treatment Division, Hospital de Olhos de Araraquara, Araraquara, Brazil
  • J. Cardillo
    Retinal Diagnostic and Treatment Division, Hospital de Olhos de Araraquara, Araraquara, Brazil
  • F. J. Rodriguez
    Vitreoretinal, Fundacion Oftalmologica Nacional, Bogota, Colombia
  • Pan American Collaborative Retina Study Group (PACORES)
    Vitreoretinal, Instituto de Cirugia Ocular, Plaza Mayor San Jose, Costa Rica
  • Footnotes
    Commercial Relationships L. Wu, None; T. Evans, None; J.F. Arevalo, None; M.H. Berrocal, None; J.A. Roca, None; M. Maia, None; R. Costa, None; J. Cardillo, None; F.J. Rodriguez, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 1547. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L. Wu, T. Evans, J. F. Arevalo, M. H. Berrocal, J. A. Roca, M. Maia, R. Costa, J. Cardillo, F. J. Rodriguez, Pan American Collaborative Retina Study Group (PACORES); Short Term Visual and Anatomic Outcomes Following Intravitreal Bevacizumab in the Treatment of Macular Edema Secondary to Central Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1547.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: To describe the short term visual and anatomic outcomes of an intravitreal injection of 1.25 mg or 2.5 mg of bevacizumab in eyes with macular edema secondary to central retinal vein occlusion.

Methods:: Interventional retrospective multicenter case series of 52 eyes with macular edema secondary to central retinal vein occlusion treated with an intravitreal injection of either 1.25 mg or 2.5 mg of bevacizumab. Visual acuity, ophthalmoscopic, fluorescein angiographic and OCT findings were recorded at baseline and last follow-up.

Results:: After an average follow-up of 23.3 weeks (range 4 to 56 weeks), the baseline logMAR visual acuity improved from 1.40 ± 0.60 to 1.10 ± 0.69 at 1 month (p=0.0331), 1.18 ± 0.65 at 3 months (p<0.0006), 1.09 ± 0.68 at 6 months (p=0.0574) and 1.12 ± 0.68 (p=0.0414) at the last follow up. Central macular thickness decreased from 566 ± 239 µm to 306 ± 102 µm (p<0.0001) at 1 month, 360 ± 213 µm at 3 months (p<0.0001), 247 ± 189 µm at 6 months (p<0.0001) and 305 ± 159 µm (p<0.0001) at the last follow-up. On average, patients received 1.9 injections per eye (range 1 to 6). Eighteen eyes (35%) received 2 injections at a mean of 8 weeks, 10 eyes (19%) 3 injections, 2 eyes (3.8%) 4 injections and one eye (1.9%) 6 injections. At the last follow-up, 23 eyes (44.2%) remained within 2 lines of baseline VA, 24 eyes (46.2%) improved 3 or more lines of ETDRS VA and 5 (9.6%) lost more than 3 lines of ETDRS VA. All 12 eyes with baseline rubeosis iridis or retinal neovascularization had disappearance of their neovascularization following the bevacizumab injection. No ocular or systemic complications were reported.

Conclusions:: Despite the small number of eyes and the short follow up in this series, it appears that intravitreal injections of bevacizumab might be a useful treatment in this condition.

Keywords: vascular occlusion/vascular occlusive disease 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×